Omeros Corp.
- OMER · Nasdaq
- Pharmaceutical Preparations
- Seattle, WA
- 175 employees
- CIK 0001285819
Updated from SEC filings through
Top things to know
Executives
- Gregory A. Demopulos MD Chairman, CEO & President 4, 2026-07-24
- Andreas Grauer, M.D. chief medical officer 10-K, 2026-03-31
- David W. Ghesquiere chief business development officer 10-K, 2026-03-31
- Nadia Dac chief commercial officer 10-K, 2026-03-31
- J. Steven Whitaker, M.D., J.D. vice president, clinical development 10-K, 2026-03-31
- Mariana N. Dimitrova, Ph.D. vice president, chemistry, manufacturing, and controls (“CMC”) 10-K, 2026-03-31
Omeros Corp is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Seattle, WA. It trades as OMER on Nasdaq. Revenue was $73.8M in the fiscal year ending December 31, 2020. It reported about 175 employees. Gregory A. Demopulos MD is Chairman, CEO & President.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | Not on file | Not on file | Not on file | Not on file | Not on file |
| Operating income | -$123M 10-K, 2026-03-31 | -$167M 10-K, 2026-03-31 | -$165M 10-K, 2026-03-31 | -$163M 10-K, 2025-03-31 | -$174M 10-K, 2024-04-01 |
| SG&A | $41.5M 10-K, 2026-03-31 | $47.4M 10-K, 2026-03-31 | $49.7M 10-K, 2026-03-31 | $50.7M 10-K, 2025-03-31 | $54.8M 10-K, 2024-04-01 |
| Net income | -$3.4M 10-K, 2026-03-31 | -$157M 10-K, 2026-03-31 | -$118M 10-K, 2026-03-31 | $47.4M 10-K, 2025-03-31 | $194M 10-K, 2024-04-01 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Gregory A. Demopulos MD | Chairman, CEO & President | 4, 2026-07-24 |
| Andreas Grauer, M.D. | chief medical officer | 10-K, 2026-03-31 |
| David W. Ghesquiere | chief business development officer | 10-K, 2026-03-31 |
| Nadia Dac | chief commercial officer | 10-K, 2026-03-31 |
| J. Steven Whitaker, M.D., J.D. | vice president, clinical development | 10-K, 2026-03-31 |
| Mariana N. Dimitrova, Ph.D. | vice president, chemistry, manufacturing, and controls (“CMC”) | 10-K, 2026-03-31 |
| Peter W. Williams | vice president, human resources | 10-K, 2026-03-31 |
| David J. Borges | VP, Finance & CAO | 4, 2026-09-24 |
| Peter B. Cancelmo Vice President, General Counsel & Corporate Secretary at Omeros Corporation | VP, General Counsel | 4, 2026-09-01 |
| Joseph Schocken | director | 8-K, 2026-08-13 |
| Arnold C. Hanish | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Diana T. Perkinson, M.D. | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Peter A. Demopulos, M.D. | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Rajiv Shah, M.D. | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Thomas F. Bumol, Ph.D. | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
| Thomas J. Cable | Board member (per proxy) bio: Director | DEF 14A, 2026-04-30 |
What Omeros Corp does
Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 72.4 million (as of August 7, 2026) | 10-Q, August 12, 2026 |
|---|---|---|
| Public float | $172M (as of June 30, 2025) | 10-K, March 31, 2026 |
| Reportable segments | 1 (period ending June 30, 2026) | 10-Q, August 12, 2026 |
| Latest proxy statement | Meeting June 18, 2026 (filed April 30, 2026) | DEF 14A, April 30, 2026 |
| Auditor | Ernst & Young LLP (Seattle, Washington) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 23, 2026 | David J. Borges VP, Finance & CAO | Sale | 20,000 | $419K | Form 4, September 24, 2026 |
| August 31, 2026 | Peter B. Cancelmo VP, General Counsel | Sale | 50,000 | $930K | Form 4, September 1, 2026 |
| August 27, 2026 | Arnold C. Hanish Director | Sale | 15,000 | $282K | Form 4, August 28, 2026 |
| August 24, 2026 | David J. Borges VP, Finance & CAO | Sale | 10,906 | $207K | Form 4, August 25, 2026 |
| August 20, 2026 | Thomas J. Cable Director | Sale | 15,000 | $277K | Form 4, August 21, 2026 |
| August 13, 2026 | David J. Borges VP, Finance & CAO | Sale | 5,000 | $85K | Form 4, August 17, 2026 |
| May 22, 2026 | Thomas J. Cable Director | Sale | 7,500 | $87K | Form 4, May 27, 2026 |
| January 13, 2026 | David J. Borges VP, Finance & CAO | Sale | 60,000 | $751K | Form 4, January 14, 2026 |
Recent 8-K events
- 8-K filed 2026-10-30
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-13
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-12
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-20
- Item 8.01 Other events
- 8-K filed 2026-07-06
- Item 8.01 Other events
- 8-K filed 2026-06-25
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-18
- Item 8.01 Other events
- 8-K filed 2026-05-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-31
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-01-07
- Item 2.02 Results of operations and financial condition (earnings release)
Frequently asked questions about Omeros Corp
- What does Omeros Corp do?
- In its own words, from Item 1 of its 10-K: "Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders."
- What is Omeros Corp's revenue?
- $73.8M for the fiscal year ending December 31, 2020, from its 10-K filed March 1, 2021.
- How many employees does Omeros Corp have?
- About 175 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Omeros Corp?
- Gregory A. Demopulos MD, Chairman, CEO & President, as named in a 4 filed July 24, 2026.
- Where is Omeros Corp headquartered?
- Seattle, WA.
- What is Omeros Corp's stock ticker?
- OMER on Nasdaq.
- What industry is Omeros Corp in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Omeros Corp's website?
- omeros.com.
- When does Omeros Corp report earnings next?
- November 12, 2026. Source: pg_future_events.
- Is Omeros Corp a public company?
- Yes. Omeros Corp files with the SEC under CIK 0001285819 and trades as OMER.
- Who audits Omeros Corp?
- Ernst & Young LLP, Seattle, Washington, as named in its latest annual report (10-K).
- How many shares of Omeros Corp are outstanding?
- 72.4 million shares as of August 7, 2026, from its 10-Q filed August 12, 2026.
- What is Omeros Corp's public float?
- $172M as of June 30, 2025, as reported on the cover of its 10-K filed March 31, 2026.
- How many business segments does Omeros Corp report?
- 1 reportable segment for the period ending June 30, 2026, from its 10-Q filed August 12, 2026.
- When is Omeros Corp's annual shareholder meeting?
- June 18, 2026, per its proxy statement (DEF 14A) filed April 30, 2026.
- Have Omeros Corp insiders traded stock recently?
- Since January 13, 2026, officers and directors reported 8 open-market sales worth about $3.0M and 0 purchases on Forms 4 and 5. The most recent: David J. Borges (VP, Finance & CAO) sold 20,000 shares on September 23, 2026.